The small molecule with a big future

Dr Oki O’Connor on Cyclarity’s elegant solution to one of the world’s biggest problems – atherosclerosis.

Cyclarity Therapeutics is on a mission to deliver affordable therapy for the world’s number one killer – cardiovascular disease. Its novel cyclodextrin targets atherosclerosis, removing arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls.

My take on this: With in-human clinical trials likely to start this year, Cyclarity is rapidly progressing its cyclodextrin drug for atherosclerosis towards market. I caught up with its CEO of Scientific Affairs, Dr Matthew ‘Oki’ O’Connor to find out more about the company’s platform, its cyclodextrin drug and his views on the current market.

Oki O’Connor on…

A unique platform

Cyclarity has designed a specialised computation screening platform that is optimised for the kind of molecule that we’re studying. We developed something completely unique that allows us to model in silico, and at various levels from fast models down to very detailed dynamic simulations, and that can predict affinity and affinity constants – that is, how strong drug candidates can grab on a target molecule that we want to target a drug against. That all goes on in silico before we synthesise a new drug candidate.

Watch the full interview HERE.

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!